Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLS009
MIFTS: 51

Plasma Cell Neoplasm

Categories: Cancer diseases, Immune diseases, Blood diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Plasma Cell Neoplasm

About this section

MalaCards integrated aliases for Plasma Cell Neoplasm:

Name: Plasma Cell Neoplasm 12 14 69
Plasma Cell Dyscrasia 12 69
Paraproteinemias 41 69
Plasma Cell Tumour 12
Plasmacytic Tumor 12
Multiple Myeloma 69
Plasmacytoma 69

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Immune diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:6536
MeSH 41 D010265
SNOMED-CT 64 277576009 71390001
Sources

Summaries for Plasma Cell Neoplasm

About this section
MalaCards based summary : Plasma Cell Neoplasm, also known as plasma cell dyscrasia, is related to monoclonal paraproteinemia and extramedullary plasmacytoma. An important gene associated with Plasma Cell Neoplasm is MYOM2 (Myomesin 2), and among its related pathways/superpathways are B cell receptor signaling pathway (KEGG) and Epstein-Barr virus infection. The drugs Dexamethasone and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are cellular and hematopoietic system

Sources

Related Diseases for Plasma Cell Neoplasm

About this section

Diseases related to Plasma Cell Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 153)
# Related Disease Score Top Affiliating Genes
1 monoclonal paraproteinemia 33.9 CD40LG CD79A
2 extramedullary plasmacytoma 30.7 B2M IL6
3 heavy chain disease 30.2 CD40LG CD79A
4 plasmacytoma 29.7 B2M CD38 CD79A IL6 MYC NCAM1
5 myeloma, multiple 28.4 B2M CD19 CD38 CD40LG CD79A IL6
6 refractory plasma cell neoplasm 12.1
7 necrobiotic xanthogranuloma 11.4
8 selective igg deficiency disease 10.6 CD40LG CD79A
9 c1q nephropathy 10.6 CD40LG CD79A
10 meningovascular neurosyphilis 10.6 CD40LG CD79A
11 alpha chain disease 10.6 CD40LG CD79A
12 brill-zinsser disease 10.6 CD40LG CD79A
13 exudative glomerulonephritis 10.6 CD40LG CD79A
14 cork-handlers' disease 10.6 CD40LG CD79A
15 salpingo-oophoritis 10.6 CD40LG CD79A
16 early yaws 10.6 CD40LG CD79A
17 ventilation pneumonitis 10.6 CD40LG CD79A
18 chronic interstitial cystitis 10.6 CD40LG CD79A
19 axillary adenitis 10.6 CD40LG CD79A
20 cryofibrinogenemia 10.6 CD40LG CD79A
21 trichostrongyloidiasis 10.6 CD40LG CD79A
22 subacute bacterial endocarditis 10.6 CD40LG CD79A
23 heterophyiasis 10.6 CD40LG CD79A
24 immunoglobulin g deficiency 10.6 CD40LG CD79A
25 orbital granuloma 10.6 CD40LG CD79A
26 hyperglobulinemic purpura 10.5 CD40LG CD79A
27 gastroduodenitis 10.5 CD40LG CD79A
28 bacterial conjunctivitis 10.5 CD40LG CD79A
29 indolent myeloma 10.5 B2M MYOM2
30 ophthalmia neonatorum 10.5 CD40LG CD79A
31 encapsulated thymoma 10.5 CD38 CD79A
32 immunoglobulin a deficiency 1 10.5 CD40LG CD79A
33 parotid disease 10.5 CD40LG CD79A
34 cerebral arteritis 10.5 CD40LG CD79A
35 selective immunoglobulin deficiency disease 10.5 CD40LG CD79A
36 smoldering myeloma 10.5 CD79A MYOM2
37 sclerosing keratitis 10.5 B2M CD79A
38 geniculate herpes zoster 10.5 CD40LG CD79A
39 erythema elevatum diutinum 10.5 CD40LG CD79A
40 sporotrichosis 10.5 CD40LG CD79A
41 fallopian tube disease 10.5 CD40LG CD79A
42 hyperimmunoglobulin syndrome 10.5 CD40LG CD79A
43 congenital syphilis 10.5 CD40LG CD79A
44 orthostatic proteinuria 10.5 B2M CD79A
45 salpingitis 10.4 CD40LG CD79A
46 mononeuritis multiplex 10.4 CD40LG MAG
47 ocular toxoplasmosis 10.4 CD40LG CD79A
48 hypersensitivity reaction type iv disease 10.4 CD40LG CD79A MYOM2
49 miller fisher syndrome 10.4 CD40LG MAG
50 upper respiratory tract disease 10.4 CD40LG CD79A MYOM2

Comorbidity relations with Plasma Cell Neoplasm via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Bronchitis
Chronic Kidney Failure Deficiency Anemia
Heart Disease Monoclonal Paraproteinemia
Neutropenia Osteoporosis

Graphical network of the top 20 diseases related to Plasma Cell Neoplasm:



Diseases related to Plasma Cell Neoplasm
Sources

Symptoms & Phenotypes for Plasma Cell Neoplasm

About this section

MGI Mouse Phenotypes related to Plasma Cell Neoplasm:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.14 MYC CD38 NCAM1 CD40LG NUP214 CD79A
2 hematopoietic system MP:0005397 10.06 CD38 CD40LG CD79A PCSK5 IL6 B2M
3 immune system MP:0005387 10 CD38 CD40LG CD79A PCSK5 IL6 B2M
4 digestive/alimentary MP:0005381 9.91 MYC NSD2 IL6 B2M CD19 PCSK5
5 mortality/aging MP:0010768 9.9 CD19 MYC NCAM1 CD40LG NSD2 NUP214
6 neoplasm MP:0002006 9.43 MYC CD79A IL6 B2M CD19 PTPRC
7 nervous system MP:0003631 9.32 MYC NCAM1 CD40LG CD79A IL6 B2M
Sources

Drugs & Therapeutics for Plasma Cell Neoplasm

About this section

Drugs for Plasma Cell Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 691)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 148-82-3 460612 4053
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
5
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
6
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
7
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24356-66-9 21704 32326
8
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-98-1 2478
9
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
10
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
11
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
12
Lenalidomide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 191732-72-6 216326
13
Apixaban Approved Phase 4,Phase 3,Phase 2 503612-47-3 10182969
14
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
15
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
16
Phentolamine Approved Phase 4 50-60-2 5775
17
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
18 Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1 52-24-4 5453
19
Tazobactam Approved Phase 4,Phase 3 89786-04-9 123630
20
Piperacillin Approved Phase 4,Phase 3 66258-76-2 43672
21 Ixazomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1072833-77-2
22
Liraglutide Approved Phase 4 204656-20-2 44147092
23
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 56-40-6 750
24
Pirarubicin Investigational Phase 4 72496-41-4
25
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
26 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1177-87-3
27 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Serine Proteinase Inhibitors Phase 4,Phase 3,Phase 2
31 Myeloma Proteins Phase 4,Phase 3,Phase 2,Phase 1
32 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
34 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Hematinics Phase 4,Phase 3,Phase 2
36 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Diphosphonates Phase 4,Phase 3,Phase 2,Phase 1
41 Paraproteins Phase 4,Phase 3,Phase 2,Phase 1
42 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1
47 Epoetin alfa Phase 4,Phase 3,Phase 2 113427-24-0
48 Hypoglycemic Agents Phase 4,Phase 1,Phase 2
49 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2452)

# Name Status NCT ID Phase Drugs
1 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
2 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
3 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
4 Pseudohyponatremia of Multiple Myeloma is True Hyponatremia Unknown status NCT01425606 Phase 4
5 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
6 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone
7 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4 Bortezomib
8 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
9 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
10 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Completed NCT00622505 Phase 4 zoledronic acid
11 A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure Completed NCT01241396 Phase 4
12 Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib Completed NCT01060202 Phase 4 No intervention
13 Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. Completed NCT01026701 Phase 4 bortezomib
14 Quality of Life in Multiple Myeloma Patients Treated With Bortezomib Completed NCT01021592 Phase 4 bortezomib
15 A Retreatment Study With Bortezomib for Multiple Myeloma Completed NCT01030302 Phase 4 bortezomib
16 Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma Completed NCT02474563 Phase 4 Bortezomib;Melphalan;Prednisone
17 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Completed NCT00257114 Phase 4 bortezomib
18 An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade Completed NCT01675245 Phase 4 No intervention
19 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
20 REmoval of Free Light Chains. A COmpaRison of Three Different dialyzERs Completed NCT02950389 Phase 4
21 VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands Completed NCT00440765 Phase 4 bortezomib
22 ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. Completed NCT00440479 Phase 4 Bortezomib
23 Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) Completed NCT01005628 Phase 4 bortezomib
24 Retrospective Survey of Re-treatment With Bortezomib Completed NCT01524445 Phase 4
25 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
26 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
27 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
28 Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients Completed NCT00195533 Phase 4 piperacillin-tazobactam;glycopeptide
29 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
30 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
31 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
32 Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation Completed NCT01738373 Phase 4 Plerixafor
33 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Recruiting NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
34 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
35 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
36 An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
37 PDD vs PAD to Treat Initially Diagnosed MM Recruiting NCT02577783 Phase 4 Chemotherapy with PDD regimen;Chemotherapy with PAD regimen
38 Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse Active, not recruiting NCT01087008 Phase 4 zoledronic acid
39 Modified Bortezomib-based Combination Therapy for Multiple Myeloma Active, not recruiting NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
40 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Not yet recruiting NCT02958969 Phase 4 Apixaban;Placebo Oral Tablet
41 Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. Not yet recruiting NCT02006225 Phase 4 Plerixafor
42 Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat Not yet recruiting NCT02920190 Phase 4 Liraglutide
43 Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
44 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4 Epoetin Beta
45 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
46 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
47 Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
48 Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
49 Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
50 Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate

Search NIH Clinical Center for Plasma Cell Neoplasm

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: paraproteinemias

Sources

Genetic Tests for Plasma Cell Neoplasm

About this section
Sources

Anatomical Context for Plasma Cell Neoplasm

About this section

MalaCards organs/tissues related to Plasma Cell Neoplasm:

38
Bone, Bone Marrow, T Cells, B Cells, Kidney, Testes, Myeloid
Sources

Publications for Plasma Cell Neoplasm

About this section

Articles related to Plasma Cell Neoplasm:

(show top 50) (show all 55)
# Title Authors Year
1
Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms. ( 29403080 )
2018
2
Plasma cell neoplasm with plasmablastic morphology mimicking acute leukemia. ( 28057674 )
2017
3
Aberrant CD3 Expression in a Relapsed Plasma Cell Neoplasm. ( 29268594 )
2017
4
Plasma cell neoplasm as a risk factor for early thrombosis of arteriovenous fistula. ( 28762615 )
2017
5
Dual CD3 and CD4 positive plasma cell neoplasm with indistinct morphology: a diagnostic pitfall. ( 27133529 )
2016
6
Plasma Cell Neoplasm Manifesting Initially as a Sub-Cutaneous Supra-Orbital Swelling. ( 26955130 )
2016
7
Collision Tumor With Renal Cell Carcinoma and Plasmacytoma: Further Evidence of a Renal Cell and Plasma Cell Neoplasm Relationship? ( 27175345 )
2016
8
Cytology of plasma cell rich effusion in cases of plasma cell neoplasm. ( 27756988 )
2016
9
Accuracy of Bone Marrow Flow Cytometry Analysis in Patients With Plasma Cell Neoplasm in Thailand: A Single Institutional Study. ( 26796980 )
2016
10
Pediatric Pharyngeal IgD-positive Monoclonal Plasmacytoid and Plasma Cell Neoplasm. ( 25851555 )
2015
11
Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains. ( 26339430 )
2015
12
Osseous plasma cell neoplasm of the mandible for initial diagnosis of multiple myeloma: case report and literature review. ( 25861199 )
2015
13
Crystal-storing histiocytosis with IgD I_-associated plasma cell neoplasm. ( 25028748 )
2014
14
Nodal involvement of extranodal marginal zone lymphoma with extreme plasmacytic differentiation (Mott cell formation) simulating plasma cell neoplasm and lymphoplasmacytic lymphoma. ( 25548763 )
2014
15
Classical Hodgkin lymphoma with coexistant plasma cell neoplasm: A case report. ( 25308039 )
2014
16
Image of the month : a rare presentation of a plasma cell neoplasm. ( 25333092 )
2014
17
Epstein-Barr virus-driven bone marrow aplasia and plasmacytosis mimicking a plasma cell neoplasm. ( 24405048 )
2014
18
Practical diagnostic approaches to composite plasma cell neoplasm and low grade B-cell lymphoma/clonal infiltrates in the bone marrow. ( 24395190 )
2014
19
Plasma cell neoplasm associated chronic neutrophilic leukemia with membrane proximal and truncating CSF3R mutations. ( 24033109 )
2013
20
Low levels of interleukin-1 receptor antagonist (IL-1RA) predict engraftment syndrome after autologous stem cell transplantation in POEMS syndrome and other plasma cell neoplasms. ( 23792270 )
2013
21
Intracellular and extracellular immunoglobulin crystals assuming a multitude of geometric shapes in an IgG-I> plasma cell neoplasm. ( 23720061 )
2013
22
Dysmegakaryocytopoiesis and maintaining platelet count in patients with plasma cell neoplasm. ( 23814762 )
2013
23
Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone. ( 22429092 )
2012
24
Familial haemophagocytic lymphohistiocytosis-related plasma cell neoplasm: a case report. ( 22774220 )
2012
25
CD3 expression in plasma cell neoplasm (multiple myeloma): a diagnostic pitfall. ( 23172088 )
2012
26
Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH. ( 22658896 )
2012
27
Lower incidence of plasma cell neoplasm is maintained in migrant Chinese to British Columbia: findings from a 30-year survey. ( 21851219 )
2011
28
Plasma cell neoplasm in conjunction with glioblastoma of the conus medullaris. ( 21325257 )
2011
29
A quantitative analysis of genomic instability in lymphoid and plasma cell neoplasms based on the PIG-A gene. ( 20060400 )
2010
30
Mandibular radiolucency. Plasma cell neoplasm. ( 19906620 )
2009
31
Ophthalmic presentation of plasma cell neoplasm. ( 19617795 )
2009
32
Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. ( 17363561 )
2007
33
Clinical implication of centrosome amplification in plasma cell neoplasm. ( 16373658 )
2006
34
CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms. ( 16759389 )
2006
35
Myc translocations in B cell and plasma cell neoplasms. ( 16815105 )
2006
36
Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. ( 15735016 )
2005
37
Peripheral neuropathy associated with experimental plasma cell neoplasm in the mouse. ( 3029337 )
1987
38
Treatment of plasma cell neoplasm with recombinant leukocyte A interferon and human lymphoblastoid interferon. ( 3917376 )
1985
39
Thyroid-gland plasma cell neoplasm (plasmacytoma). ( 7027992 )
1981
40
An unusual case of a plasma cell neoplasm with an IgG3lambda myeloma and a gamma3 heavy chain disease protein. ( 412532 )
1978
41
Plasma cell neoplasm involving the thyroid. ( 638958 )
1978
42
Tumor cell invasion of hepatocytes in transplantable plasma cell neoplasm of mice. ( 4344454 )
1972
43
Ploidy fluctuations of mouse plasma-cell neoplasm MSPC-1 during serial transplantation. ( 5157581 )
1971
44
Enzymatic determinants of responsiveness of the LPC-1 plasma cell neoplasm to fluorouracil and fluorodeoxyuridine. ( 4254308 )
1970
45
Studies on the murine plasma-cell neoplasm, X5563. II. Accelerated immunologic reactivity to transplanted tumor induced in C3H mice by transferred immune rabbit cells. ( 6053557 )
1967
46
PLASMA CELL NEOPLASM ARISING IN A CAF MOUSE. CHARACTERISTICS AND RESPONSE TO CERTAIN CHEMOTHERAPEUTIC AGENTS. ( 14207853 )
1964
47
BIOCHEMICAL EFFECTS OF DUAZOMYCIN A IN THE MOUSE PLASMA CELL NEOPLASM 70429. ( 14096421 )
1963
48
Azaserine resistance in a plasma-cell neoplasm without change in active transport of the inhibitor. ( 13861221 )
1962
49
A study on globulin formation by plasma-cell neoplasm (5563) transplantable in mice. ( 13684805 )
1961
50
Distinctive myeloma globulins associated with a new plasma cell neoplasm of strain C3H mice. ( 13821296 )
1960
Sources

Variations for Plasma Cell Neoplasm

About this section

Copy number variations for Plasma Cell Neoplasm from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17396 1 142600000 155000000 Gain Plasma-cell dyscrasia
Sources

Expression for Plasma Cell Neoplasm

About this section
Search GEO for disease gene expression data for Plasma Cell Neoplasm.
Sources

Pathways for Plasma Cell Neoplasm

About this section

Pathways related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
B cell receptor signaling pathway (KEGG) 1
Show member pathways
 12.13 CD19 CD79A MYC PTPRC
2
Epstein-Barr virus infection 36
12.04 CD19 CD38 MYC NUP214
3
NF-kappaB Signaling 4
12.01 B2M CD19 CD38 CD40LG CD79A NCAM1
4
Cell adhesion molecules (CAMs) 36
11.87 CD40LG MAG NCAM1 PTPRC
5
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 62
11.83 B2M CD19 CD40LG
6
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 61
11.81 IL6 MYC NCAM1
7
Spinal Cord Injury 1
11.75 IL6 MAG MYC
8
Hematopoietic cell lineage 36
11.64 CD19 CD38 IL6
9
Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers 61
11.64 CD19 CD79A IL6 NCAM1 PTPRC
10
Dendritic Cells Developmental Lineage Pathway 61
11.42 CD19 CD38 IL6 NCAM1 PTPRC
11
B Cell Development Pathways 61
11.39 CD19 CD38 CD40LG PTPRC
12
Primary immunodeficiency 36
11.19 CD19 CD40LG CD79A PTPRC
13
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 61
11.16 CD19 CD38 CD79A IL6 NCAM1 PTPRC
Sources

GO Terms for Plasma Cell Neoplasm

About this section

Cellular components related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 B2M CD38 CD40LG NCAM1 PTPRC
2 external side of plasma membrane GO:0009897 9.1 B2M CD19 CD40LG CD79A NCAM1 PTPRC

Biological processes related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of T cell proliferation GO:0042102 9.33 CD40LG IL6 PTPRC
2 negative regulation of bone resorption GO:0045779 9.26 CD38 IL6
3 B cell proliferation GO:0042100 9.13 CD40LG CD79A PTPRC
4 B cell receptor signaling pathway GO:0050853 8.92 CD19 CD38 CD79A PTPRC
Sources

Sources for Plasma Cell Neoplasm

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....